https://www.nasdaq.com/press-release/amarin-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference-2022-01-04
https://www.nasdaq.com/press-release/amarin-reports-overview-of-latest-clinical-research-evaluating-vascepar-vazkepa-0
https://www.nasdaq.com/press-release/amarin-reports-subgroup-data-from-reduce-itr-highlighting-benefits-of-vascepar
https://www.nasdaq.com/press-release/amarin-to-present-at-two-upcoming-investor-conferences-2021-11-11
https://www.nasdaq.com/press-release/amarin-reports-third-quarter-2021-financial-results-and-provides-business-update-2021
https://www.nasdaq.com/press-release/amarin-to-report-third-quarter-2021-financial-results-and-host-conference-call-on
https://www.nasdaq.com/press-release/amarin-outlines-new-go-to-market-strategy-to-accelerate-vascepar-icosapent-ethyl
https://www.nasdaq.com/press-release/amarin-announces-first-european-launch-of-vazkepa-icosapent-ethyl-in-germany-2021-09
https://www.nasdaq.com/press-release/amarin-to-participate-in-september-investment-conferences-2021-09-13
https://www.nasdaq.com/press-release/amarin-reports-overview-of-latest-clinical-research-evaluating-vascepar-vazkepa
https://www.nasdaq.com/press-release/amarin-reports-data-from-reduce-itr-showing-vascepar-vazkepa-icosapent-ethyl
https://www.nasdaq.com/press-release/latest-clinical-research-evaluating-vascepar-vazkepa-icosapent-ethyl-in-patients-with
https://www.nasdaq.com/press-release/amarin-reports-second-quarter-and-six-month-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/amarin-to-report-second-quarter-and-six-month-2021-financial-results-and-host
https://www.nasdaq.com/press-release/further-insights-into-mechanism-of-action-of-icosapent-ethyl-and-its-unique-form-of
https://www.nasdaq.com/press-release/amarin-to-present-at-two-investor-conferences-in-june-2021-2021-05-18
https://www.nasdaq.com/press-release/amarin-highlights-multiple-scientific-findings-for-vascepar-icosapent-ethyl-and-its
https://www.nasdaq.com/press-release/reduce-itr-heart-failure-analyses-by-vascepar-icosapent-ethyl-driven-serum
https://www.nasdaq.com/press-release/clinical-data-and-other-research-results-regarding-vascepar-icosapent-ethyl-and-its
https://www.nasdaq.com/press-release/amarin-reports-first-quarter-2021-financial-results-and-provides-business-update-2021
https://www.nasdaq.com/press-release/amarin-announces-planned-retirement-of-joseph-t.-kennedy-evp-general-counsel-2021-04
https://www.nasdaq.com/press-release/amarin-receives-great-britain-marketing-authorization-for-vazkepa-from-the-medicines
https://www.nasdaq.com/press-release/amarin-to-report-first-quarter-results-and-host-conference-call-on-april-29-2021-2021
https://www.nasdaq.com/press-release/vascepar-icosapent-ethyl-reported-to-impact-vulnerable-coronary-plaque-features-in
https://www.nasdaq.com/press-release/amarin-announces-ceo-succession-plan-2021-04-12
https://www.nasdaq.com/press-release/amarin-commences-commercial-initiatives-for-vazkepa-in-european-union-following
https://www.nasdaq.com/press-release/amarin-receives-european-commission-ec-approval-for-vazkepa-to-reduce-cardiovascular
https://www.nasdaq.com/press-release/fifteen-medical-societies-now-recommend-icosapent-ethyl-to-reduce-cardiovascular-risk
https://www.nasdaq.com/press-release/vascepar-icosapent-ethyl-found-in-prespecified-and-post-hoc-analyses-to-significantly
https://www.nasdaq.com/press-release/amarin-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/amarin-to-present-at-two-upcoming-investor-conferences-2021-02-18
https://www.nasdaq.com/press-release/amarin-to-report-fourth-quarter-and-full-year-2020-results-and-host-conference-call
https://www.nasdaq.com/press-release/amarin-provides-update-on-vascepar-icosapent-ethyl-regulatory-review-processes-in
https://www.nasdaq.com/press-release/amarin-receives-positive-chmp-opinion-for-icosapent-ethyl-for-cardiovascular-risk
https://www.nasdaq.com/press-release/amarin-expands-cardiovascular-risk-reduction-patent-infringement-lawsuit-to-include
https://www.nasdaq.com/press-release/icosapent-ethyl-included-in-the-chinese-society-of-cardiology-csc-updated-guidelines
https://www.nasdaq.com/press-release/amarin-provides-preliminary-2020-results-and-2021-outlook-2021-01-07
https://www.nasdaq.com/press-release/amarin-to-present-at-39th-annual-j.p.-morgan-healthcare-conference-2021-01-04
https://www.nasdaq.com/press-release/amarin-highlights-multiple-vascepar-icosapent-ethyl-related-scientific-findings
https://www.nasdaq.com/press-release/amarin-reports-encouraging-efficacy-and-safety-results-from-pilot-study-treating
https://www.nasdaq.com/press-release/vascepar-icosapent-ethyl-related-scientific-findings-to-be-presented-at-national
https://www.nasdaq.com/press-release/amarin-files-patent-infringement-lawsuit-against-hikma-2020-11-30
https://www.nasdaq.com/press-release/amarin-to-present-at-piper-sandlers-32nd-annual-healthcare-conference-virtual-2020-11
https://www.nasdaq.com/press-release/amarin-shares-topline-data-from-partners-pivotal-phase-3-study-of-vascepar-icosapent
https://www.nasdaq.com/press-release/multiple-new-vascepar-icosapent-ethyl-related-scientific-findings-presented-at
https://www.nasdaq.com/press-release/amarin-to-present-at-the-stifel-2020-virtual-healthcare-and-jefferies-virtual-london
https://www.nasdaq.com/press-release/amarin-reports-third-quarter-2020-financial-results-and-provides-business-update-2020
https://www.nasdaq.com/press-release/new-vascepar-icosapent-ethyl-related-scientific-findings-to-be-presented-at-american
https://www.nasdaq.com/press-release/u.s.-veterans-with-decreased-renal-function-shown-to-be-at-higher-risk-for-adverse
https://www.nasdaq.com/press-release/amarin-to-report-third-quarter-2020-results-and-host-conference-call-on-november-5
https://www.nasdaq.com/press-release/latest-research-evaluating-vascepar-icosapent-ethyl-mechanisms-of-action-presented-at
https://www.nasdaq.com/press-release/amarin-to-present-at-the-2020-cantor-virtual-global-healthcare-conference-2020-09-09
https://www.nasdaq.com/press-release/amarin-provides-update-following-ruling-in-vascepar-anda-patent-litigation-2020-09-03
https://www.nasdaq.com/press-release/amarin-supports-latest-clinical-research-evaluating-vascepar-icosapent-ethyl-in
https://www.nasdaq.com/press-release/vascepar-icosapent-ethyl-reported-to-significantly-reduce-coronary-plaque-in
https://www.nasdaq.com/press-release/latest-clinical-research-evaluating-vascepar-icosapent-ethyl-in-patients-with
https://www.nasdaq.com/press-release/latest-clinical-research-evaluating-vascepar-icosapent-ethyl-in-patients-with-0
https://www.nasdaq.com/press-release/amarin-supports-investigator-initiated-trial-at-kaiser-permanente-in-the-u.s.-to
https://www.nasdaq.com/press-release/amarin-announces-plans-to-maximize-blockbuster-potential-of-vascepar-icosapent-0
https://www.nasdaq.com/press-release/amarin-announces-plans-to-maximize-blockbuster-potential-of-vascepar-icosapent-ethyl
https://www.nasdaq.com/press-release/amarin-reports-second-quarter-2020-financial-results-and-provides-update-on
https://www.nasdaq.com/press-release/vascepar-icosapent-ethyl-data-from-reduce-itr-revasc-including-new-data-on-timeframe
https://www.nasdaq.com/press-release/amarin-to-report-second-quarter-2020-results-and-host-conference-call-on-august-4
https://www.nasdaq.com/press-release/amarin-announces-patent-litigation-settlement-agreement-with-apotex-inc.-2020-06-16
https://www.nasdaq.com/press-release/vascepar-icosapent-ethyl-shows-significant-cardiovascular-risk-reduction-in-people
https://www.nasdaq.com/press-release/amarin-plans-to-increase-vascepar-icosapent-ethyl-promotion-and-education-2020-06-01
https://www.nasdaq.com/press-release/amarin-supports-trial-to-investigate-the-effects-of-vascepar-icosapent-ethyl-in-the
https://www.nasdaq.com/press-release/vascepar-icosapent-ethyl-shows-significant-reduction-in-coronary-revascularization
https://www.nasdaq.com/press-release/amarin-reports-first-quarter-2020-financial-results-and-provides-update-on-operations
https://www.nasdaq.com/press-release/amarin-to-report-first-quarter-2020-results-and-host-conference-call-on-april-30-2020
https://www.nasdaq.com/press-release/amarin-to-host-conference-call-on-april-13-2020-to-provide-preliminary-first-quarter
https://www.nasdaq.com/press-release/amarin-highlights-vascepar-icosapent-ethyl-related-data-presented-at-american-college
https://www.nasdaq.com/press-release/amarin-comments-on-ruling-in-vascepar-anda-litigation-2020-03-30
https://www.nasdaq.com/press-release/eicosapentaenoic-acid-epa-levels-from-vascepar-icosapent-ethyl-in-reduce-itr-strongly
https://www.nasdaq.com/press-release/amarin-takes-proactive-steps-to-support-public-health-priorities-2020-03-15
https://www.nasdaq.com/press-release/amarin-reports-record-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/amarin-to-present-at-two-upcoming-investor-conferences-2020-02-20
https://www.nasdaq.com/press-release/amarin-to-report-fourth-quarter-and-full-year-2019-results-and-host-conference-call
https://www.nasdaq.com/press-release/amarin-honored-by-bionj-with-innovator-award-for-vascepar-development-and-regulatory
https://www.nasdaq.com/press-release/amarin-launches-true-to-your-heart-a-campaign-to-educate-people-on-persistent
https://www.nasdaq.com/press-release/amarin-provides-update-to-preliminary-2019-results-and-further-details-on-2020
https://www.nasdaq.com/press-release/amarin-to-present-at-38th-annual-j.p.-morgan-healthcare-conference-2020-01-06
https://www.nasdaq.com/press-release/vascepar-approved-in-canada-to-reduce-the-risk-of-cardiovascular-events-2020-01-02
https://www.nasdaq.com/press-release/amarin-receives-fda-approval-of-vascepar-icosapent-ethyl-to-reduce-cardiovascular-0
https://www.nasdaq.com/press-release/amarin-receives-fda-approval-of-vascepar-icosapent-ethyl-to-reduce-cardiovascular
https://www.nasdaq.com/press-release/european-medicines-agency-accepts-for-review-marketing-authorization-application-for
https://www.nasdaq.com/press-release/amarin-highlights-key-reduce-itr-related-data-presented-at-american-heart-association
https://www.nasdaq.com/press-release/amarins-john-thero-awarded-ey-entrepreneur-of-the-yearr-2019-life-sciences-national
https://www.nasdaq.com/press-release/amarin-announced-fda-advisory-committee-voted-unanimously-16-0-to-recommend-approval
https://www.nasdaq.com/press-release/new-analysis-shows-icosapent-ethyl-vascepar-is-cost-effective-and-offers-rare-finding
https://www.nasdaq.com/press-release/reduce-itr-usa-results-in-prespecified-subgroup-analyses-of-landmark-reduce-it-global
https://www.nasdaq.com/press-release/amarin-to-present-at-the-jefferies-2019-london-healthcare-conference-2019-11-11
https://www.nasdaq.com/press-release/amarin-reports-third-quarter-2019-financial-results-and-provides-update-on-operations
https://www.nasdaq.com/press-release/seven-data-presentations-relevant-to-vascepar-icosapent-ethyl-capsules-and-persistent
https://www.nasdaq.com/press-release/amarin-to-report-third-quarter-2019-results-and-host-conference-call-on-november-5
https://www.nasdaq.com/press-release/independent-drug-pricing-assessment-finds-vascepar-icosapent-ethyl-cost-effective-as
https://www.nasdaq.com/press-release/amarin-to-participate-in-the-cantor-global-healthcare-conference-2019-09-23
https://www.nasdaq.com/press-release/national-lipid-associations-new-position-statement-on-use-of-icosapent-ethyl-in-high
https://www.nasdaq.com/press-release/amarin-amrn-alert%3a-johnson-fistel-launches-investigation-into-amarin-corporation-plc
https://www.nasdaq.com/press-release/thinking-about-trading-options-or-stock-in-apple-amarin-bp-cisco-systems-or-morgan
https://www.nasdaq.com/press-release/shareholder-alert-pomerantz-law-firm-reminds-shareholders-losses-their-investment-11
https://www.nasdaq.com/press-release/amarin-alert-gibbs-law-group-has-filed-sole-class-action-shareholders-should-contact
https://www.nasdaq.com/press-release/cardiovascular-risk-multiple-triglyceride-thresholds-highlighted-presentation
https://www.nasdaq.com/press-release/additional-real-world-data-show-significant-risk-increase-cardiovascular-events
https://www.nasdaq.com/press-release/high-risk-atherosclerotic-cardiovascular-events-projected-people-elevated
https://www.nasdaq.com/press-release/amarin-present-cowens-39th-annual-health-care-conference-2019-04-21
https://www.nasdaq.com/press-release/important-new-data-vascepar-icosapent-ethyl-reduce-ittm-trial-be-presented-regarding
https://www.nasdaq.com/press-release/amarin-investor-alert-gibbs-law-group-has-filed-sole-class-action-shareholders-should
